SELLAS Life Sciences Group, Inc.

For the period ended Jun 30, 2026. Filed Aug 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 11, 2026

SLS$8.58+1.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025

CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except share and per share data)

	June 30, 2026	December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents	$138,343	$71,793
Restricted cash and cash equivalents	100	100
Prepaid expenses and other current assets	4,062	3,318
Total current assets	142,505	75,211
Operating lease right-of-use assets	710	963
Goodwill	1,914	1,914
Deposits and other assets	253	257
Total assets	$145,382	$78,345
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$3,086	$2,948
Accrued expenses and other current liabilities	3,903	3,525
Operating lease liabilities	580	544
Total current liabilities	7,569	7,017
Operating lease liabilities, non-current	157	457
Total liabilities	7,726	7,474
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.0001 par value; 350,000,000 shares authorized, 201,918,874 and 153,103,459 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	20	15
Additional paid-in capital	430,636	345,844
Accumulated deficit	(293,000)	(274,988)
Total stockholders’ equity	137,656	70,871
Total liabilities and stockholders’ equity	$145,382	$78,345

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.